BioNTech and Pfizer's COVID-19 vaccine shows potential in hu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday (1 July).

The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.

BioNTech said testing of two dosages of its BNT162b1 drug on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.

It said the higher of the two doses - both administered via two injections within three weeks of one another - was followed by a short fever in three out of four participants after the second shot.

BioNTech and Pfizer will now pick the most promising of four experimental vaccines for a trial involving up to 30,000 healthy participants, which is likely to begin in the United States and Europe in late July if it gets the regulatory green light.

Source: https://www.jpost.com/health-science/biontech-and-pfizers-covid-19-vaccine-shows-potential-in-human-trial-633469
Dr. T●●●●z H●●●●●●i and 7 others like this8 shares
Like
Comment
Share